Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment

Phytomedicine

Volumn 16, Issue 5, 2009, Pages 401-405

  Inayat ur Rahman, ^a   Malik, Salman Akbar ^a   Bashir, Mohammad ^b   Khan, Roohullh ^c   Iqbal, Mohammad ^b  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b KOHAT UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

^c Bannu Medical College   (Pakistan)

Author keywords

Bitter melon; Cardiovascular complications; Diabetes (NIDDM); Momordica charantia Rosiglitazone; Sialic acid

Indexed keywords

CHOLESTEROL; GLUCOSE; LIPID; MOMORDICA CHARANTIA EXTRACT; ROSIGLITAZONE; SIALIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; EXPERIMENTAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MALE; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FRUIT; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MOMORDICA CHARANTIA; N-ACETYLNEURAMINIC ACID; PHYTOTHERAPY; PLANT PREPARATIONS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

CUCUMIS; MOMORDICA CHARANTIA;

EID: 64649092110     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2009.01.001     Document Type: Article

References (27)

1. Basch E., Gabardi S., and Ulbricht C. Bitter melon (momordica charantia): a review of efficacy and safety. Am. J. Health Syst. Pharm. 60 4 (2003) 356-359
2. Barnett A.H., Grant P.J., and Hitman G.A. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet. Med. 20 (2003) 387-393
3. Bouham M. Medicinal plants with potential antidiabetic activity. A review of ten years of herbal medicines research (1990-2000). Int. J. Diabetes Metab. 14 (2006) 1-25
4. Chaturvedi P. Role of momordica charantia in maintaining the normal levels of lipids and glucose in diabetic rats fed a high-fat and low-carbohydrate diet. Br. J. Biomed. Sci. 62 3 (2005) 124-126
5. Chen Q., Chan L.L.Y., and Li E.T.S. Bitter melon reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr. 133 (2003) 1088-1093
6. Crook M.A., Earle K., and Morocutti A. Serum sialic acid, a risk factor for cardiovascular disease, is increased in IDDM patients with microalbuminuria and clinical proteinuria. Diabetes Care 17 (1994) 305-309
7. Erdman E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., and Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from PROactive (PROactive 05). J. Am. Coll. Cardiol. 49 17 (2007) 1772-1780
8. Eurich D.T., McAlister F.A., and Blackburn D.F. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br. Med. J. 335 7618 (2007) 497
9. Grover J.K., and Yadav S.P. Pharmacological actions and potential uses of momordica charantia: a review. J. Ethnopharmacol. 93 (2004) 123-132
10. Jeanloz R.W., and Codington J.F. In: Rosenberg A., and Schengrund C. (Eds). Biological Roles of Sialic Acid (1976), Plenum Press, New York, NY, USA 201-238
11. Khanderi U., Pop-Busui R., and Eagle K.A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann. Pharmacother. 42 (2008) 1466-1474
12. Krawinkel M.B., and Keding G.B. Bitter gourd (momordica charantia): a dietary approach to hyperglycemia. Nutr. Rev. 64 7 Pt 1 (2006) 331-337
13. Ledeen R.W., and Yu R.K. Chemistry and analysis of sialic acid. In: Rosenberg A., and Schengrund C. (Eds). Biological Roles of Sialic Acid (1976), Plenum Press, New York, NY, USA 1-57
14. Lindberg G., Eklund G.A., Gulberg B.O., and Rastam L. Serum sialic acid concentration and cardiovascular mortality. Results from 20.5 years follow up of 26,693 men and women. Br. Med. J. 302 (1991) 143-146
15. Lindberg G., Rastam L., Gulberg B.O., and Eklund G.A. Serum sialic acid concentration predicts coronary artery disease and stroke mortality: multivariate analysis including 54285 men and women during 30.5 year follow-up. Int. J. Epidemol. 21 (1992) 253-257
16. Lindberg G., Eklund G.A., and Gulberg B.O. Serum concentration of sialic acid and sialoglycoproteins in relation to coronary heart disease risk markers. Atherosclerosis 103 (1993) 143-146
17. McNeill, John, H., 1999-02-01. Experimental Models of Diabetes, first ed. CRC Press, Boca Raton, FL, 208pp.
18. Nerurkar P.V., Lee Y.K., Linden E.H., Lim S., Pearson L., and Frank J. Laboratories of metabolic disorder and alternative medicine, department of molecular biosciences and bioengineering, College of tropical agriculture and human resources, room 415H, East-West road, Honolulu, Hi. Br. J. Pharmacol. 148 8 (2006) 1156-1164
19. Nissen, Steven E., and Ewolksi K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 24 (2007) 2457-2471
20. Pickup J.C., Mattock M.B., Crook M.A., Chusney G.D., Burt D., and Fitzerald A.P. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 18 8 (1995) 1100-1103
21. Raman A., and Lau C. Antidiabetic properties and phytochemistry of momordica charantia. Phytomedicine 2 (1996) 349-362
22. Rendell M. Advances in diabetes for the millennium: drug therapy of type2 diabetes. Med. Gen. Med. 6 3 suppl (2004) 9 (PMID 15647714)
23. Shamberger R.J. Serum sialic acid in normal and cancer patients. Clin. Chem. Biochem. 22 (1984) 647-651
24. Tinder P. Ann. Clin. Biochem. 6 (1969) 24
25. Wakabayashi I., Sakameto K., Yoshimoto S., and Masui S. Relation of serum sialic acid to lipid concentration. Br. Med. J. 305 (1992) 562-563
26. Wood, Shelly, 2007-7-31. FDA advisory panels acknowledge signal of risk with rosiglitazone, but stop short of recommending its withdrawal. Heartwire. Retrieved on 2007-09-2.
27. Yokohama H., Jenson J.S., Jenson T., and Deckert T. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. J. Int. Med. 237 (1995) 519-523